Congress Presentations
Stay informed about the latest scientific and medical research from Axsome.
AMCP Nexus 2025
National Harbor, MD | October 27 - 30, 2025
AXS-05 | Major Depressive Disorder
Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine
AXS-05 | Major Depressive Disorder
Dr. Syed presents the "Real-world characteristics and treatment patterns of patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets, cariprazine, brexpiprazole, or esketamine" poster
AXS-05 | Major Depressive Disorder
Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder
AXS-05 | Major Depressive Disorder
Dr. Leslie Citrome presents the "Real-world healthcare utilization and costs associated with using dextromethorphan-bupropion extended-release tablets versus branded comparators for the treatment of major depressive disorder" poster
AXS-05 | Major Depressive Disorder
Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment
AXS-05 | Major Depressive Disorder
Dr. Leslie Citrome presents the "Healthcare costs for patients with major depressive disorder initiating dextromethorphan-bupropion extended-release tablets as a first or subsequent line of treatment" poster
AXS-05 | Alzheimer’s Disease Agitation
Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study
AXS-05 | Alzheimer’s Disease Agitation
Dr. Grossberg presents the "Efficacy and Safety of AXS-05 in Alzheimer's Disease Agitation: Results From ACCORD-2, a Phase 3 Randomized Withdrawal Double-Blind Placebo-Controlled Study" poster
Symbravo® | Migraine
Efficacy and Safety of Symbravo® (MoSEIC(TM) Meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
Symbravo® | Migraine
Dr. Lipton presents the "Efficacy and Safety of Symbravo® (MoSEIC(TM) Meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial" poster
Symbravo® | Migraine
Budget impact of Symbravo® (MoSEIC™meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults
Symbravo® | Migraine
Dr. Kuruvilla presents the " Budget impact of Symbravo® (MoSEIC™meloxicam and rizatriptan) to health plans in the United States for the acute treatment of migraine in adults" poster
